George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Max
Hopefully news this week but who knows?
So what do we want to hear:
•PRD approved and the company say what is the next step to getting a the voucher.
•EAP up and running
•Zero been resubmitted
•CPT been resubmitted
•GEHC and Catanic sales far exceed expectations
•Grant from Gates Foundation
•Bayer want to buy the company
•Big pharma wants to co-sponsor the trials
Any of those would be positive
Or is it more likely:
•No sales via GEHC etc
•Current partners haven’t renewed their contracts
•KS lab is looking for a new partner
•New fund raise
•PRD has been rejected
All possible
Or
• No news, just the basic accounts and a few special proposals for the AGM.
•new research by crystal and announcement the company shares should be worth 8p so the board will buy ours back for 2p and say we are making 30% on current sp.
Fingers crossed everybody. We should know in the next week or two the short term direction of the company.
Thanks
Good luck
Hopefully news soon !
Hello maximillion69,
Absolutely correct over the 300K 😉
Best, 🐸
Tyke
My call would be the 300k at 11.54 and
25k Were buys
So which of the big transaction were actually buys do we reckon?
Have a good weekend everybody
Thanks
Accounts - I struggle with reading accounts. But also laziness (mine) doesn't help. Thanks for the responses. I will try and make a big effort to spend a bit more focused time on the accounts/results. I suspect there isn't a great deal of £ washing about. I hope I'm wrong.
Evening, IB as a trading entity is profitable, as per the accounts, IQAI loses money due to UK listing costs and directors fees but UK listing required to part fund research and development of products, Dec 23 results will be interesting to see what take up there has been as per interims last August, I would have thought PRD news would have hit now, has been 2 months
I did a few dummy trades today of 100,000 sells and was offered between 1.53 and 1.51 depending on time so all 4 of todays trades were sells and not buys as reported.
Max
Looking at the last week’s trades it does look like 1.57+ are buys and anything around 1.50 are sells. But once again we just don’t know.
Xviolet
If you read the January newsletter (bottom paragraph) we may not have even submitted the revised CPT yet. So I think it may be late this year or early next before we get a code unfortunately. So again we have no idea about revenue.
Thanks
They said they need a CPT code to help with sales. They haven't got it yet. We could get bumpy results...then...in May, the light...????
From a recent RNS...
CPT Code: "Earlier this year, we made the strategic decision to apply for a Current Procedure Terminology (CPT) code specific to the DSC perfusion technology available in IB Neuro. The application is due in early November and a final decision will be made in May 2024. A CPT code will help make for easier buying decisions for healthcare administrators."
Just my thought , all the recent small 212 trades make the spread larger than actual thus harder to determine buys or sells . A lot of recent trades are showing as buys on here but I suspect as with todays trades some are sells. Any thoughts ?
It should show in the ‘trade and other receivables’ on the results. But don’t expect succinct transparency!
Usual caveats
Trek
Xviolet
Unfortunately we have no idea how many times our products have been used with regards the deals with GEHC and Bayer. Hence nobody knows the income.
Thanks
Tyke
if there have been commercial contracts they should let us know. I will spend some time pouring over the shareholders letter etc. but mainly feeling glad that I am anything but over extended in this share.
Xviolet
That is the million dollar question we are all waiting for the results to find out. We honestly don’t have a clue.
Thanks
Anyone got a ballpark on how much iq ai brings in per annum?
(that might help to explain the CEO's dealings?
Tyke 68 - well you certainly jinxed that with the comment about the buys as zero traded today which is kinda strange considering all the under £10 pocket money trades that have been going through this last week. Can't recall a zero trade day for a while.
The calm before the storm?
Lots of decent buys over the last week but no effect on the share price.
Thanks
Max
I doesn’t look like we were mentioned but no actual video or transcript.
https://cloud.withgoogle.com/next/session-library?filters=track-ai-and-ml&demo=SCT-AI1#all
Totally agree about Zero, it is about time we heard about the resubmission. It seems to have gone very quiet on announcements at the moment. Maybe a blockbuster announcement with the yearly results? We can all dream.
Thanks
Https://www.linkedin.com/posts/bayer-pharmaceuticals_radiology-bayerinradiology-ai-activity-7185607838898008064-dNqV?utm_source=share&utm_medium=member_ios
Looks like quite a show put on here maybe our tech has had a mention .
Maybe news on IB Zero G re submission
This week, annual accounts, shareholders letter😂 and PRD , which was resubmitted on the 16/2, best of luck to shareholders!
Cautious
Totally agree we are at this sp due to all the shenanigans but what I am trying to say is there must be an exit strategy by TB and no way is that at this valuation. He must know more about what is in the pipeline. As I keep saying this company must be or will be on bigger fish’s radar. TB is looking at a paper loss of £10m from what was the high point of 20p+. I think we have to be looking at a figure above that for him to sell.
Regarding KS and her involvement in other trials. It doesn’t mention IB but I would guess that they are using our technology for the imagery. The more other universities use our technology the better. Keep spreading the word etc.
Thanks
Could not agree more Cautious, I have no confidence in the board.
Anyway this might be of interest to those following the research work. Kathleen Schmainda is involved in a clinical trial. Interesting is no mention of IB, just MCW.
Here is the link. If you search for eaf223/gable and filter the results to the last week you get a few results with quite a lot of detail. It does fit in to one of the video presentations when they were discussing future work.
https://blog-ecog-acrin.org/now-enrolling-eaf223-gable-for-patients-with-glioblastoma/
The clinical trial reference is NCT06319027.
Financial results should be week after next, looking forward to seeing the figures.
Have a good weekend all
Shrek